Moderna, Inc. Cost of Revenue
Moderna, Inc. (MRNA) reported Cost of Revenue of $93.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-31
- Moderna, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $93.00M, a 21.85% decline year-over-year.
- Moderna, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $955.00M, a 961.11% increase year-over-year.
- Moderna, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $452.00M, a 38.84% decline year-over-year.
- Moderna, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $207.00M, a 59.73% decline year-over-year.
- Moderna, Inc. cost of goods and services sold for fiscal 2025 was $868.00M, a 40.71% decline from fiscal 2024.
- Moderna, Inc. cost of goods and services sold for fiscal 2024 was $1.46B, a 68.80% decline from fiscal 2023.
- Moderna, Inc. cost of goods and services sold for fiscal 2023 was $4.69B, a 13.35% decline from fiscal 2022.
- Moderna, Inc. cost of goods and services sold for fiscal 2022 was $5.42B, a 106.95% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $93.00M 10-Q · filed 2026-07-31 | $1.05B 10-Q · filed 2026-07-31 | $1.50B derived: sum of 3 quarters · filed 2026-07-31 | $1.71B derived: sum of 4 quarters · filed 2026-07-31 | |
| 2026-03-31 | $955.00M 10-Q · filed 2026-05-01 | $1.41B derived: sum of 2 quarters · filed 2026-05-01 | $1.61B derived: sum of 3 quarters · filed 2026-05-01 | $1.73B derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-12-31 | $452.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $659.00M derived: sum of 2 quarters · filed 2026-02-20 | $778.00M derived: sum of 3 quarters · filed 2026-07-31 | $868.00M 10-K · filed 2026-02-20 | |
| 2025-09-30 | $207.00M 10-Q · filed 2025-11-06 | $326.00M derived: sum of 2 quarters · filed 2026-07-31 | $416.00M 10-Q · filed 2025-11-06 | $1.16B derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-06-30 | $119.00M 10-Q · filed 2026-07-31 | $209.00M 10-Q · filed 2026-07-31 | $948.00M derived: sum of 3 quarters · filed 2026-07-31 | $1.46B derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-03-31 | $90.00M 10-Q · filed 2026-05-01 | $829.00M derived: sum of 2 quarters · filed 2026-05-01 | $1.34B derived: sum of 3 quarters · filed 2026-05-01 | $1.46B derived: sum of 4 quarters · filed 2026-05-01 | |
| 2024-12-31 | $739.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.25B derived: sum of 2 quarters · filed 2026-02-20 | $1.37B derived: sum of 3 quarters · filed 2026-02-20 | $1.46B 10-K · filed 2026-02-20 | |
| 2024-09-30 | $514.00M 10-Q · filed 2025-11-06 | $629.00M derived: sum of 2 quarters · filed 2025-11-06 | $725.00M 10-Q · filed 2025-11-06 | $1.65B derived: sum of 4 quarters · filed 2026-02-20 | |
| 2024-06-30 | $115.00M 10-Q · filed 2025-08-01 | $211.00M 10-Q · filed 2025-08-01 | $1.14B derived: sum of 3 quarters · filed 2026-02-20 | $3.38B derived: sum of 4 quarters · filed 2026-02-20 | |
| 2024-03-31 | $96.00M 10-Q · filed 2025-05-01 | $1.02B derived: sum of 2 quarters · filed 2026-02-20 | $3.27B derived: sum of 3 quarters · filed 2026-02-20 | $4.00B derived: sum of 4 quarters · filed 2026-02-20 | |
| 2023-12-31 | $929.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $3.17B derived: sum of 2 quarters · filed 2026-02-20 | $3.90B derived: sum of 3 quarters · filed 2026-02-20 | $4.69B 10-K · filed 2026-02-20 | |
| 2023-09-30 | $2.24B 10-Q · filed 2024-11-07 | $2.97B derived: sum of 2 quarters · filed 2024-11-07 | $3.76B 10-Q · filed 2024-11-07 | $5.68B derived: sum of 4 quarters · filed 2025-02-21 | |
| 2023-06-30 | $731.00M 10-Q · filed 2024-08-01 | $1.52B 10-Q · filed 2024-08-01 | $3.44B derived: sum of 3 quarters · filed 2025-02-21 | $4.54B derived: sum of 4 quarters · filed 2025-02-21 | |
| 2023-03-31 | $792.00M 10-Q · filed 2024-05-02 | $2.71B derived: sum of 2 quarters · filed 2025-02-21 | $3.81B derived: sum of 3 quarters · filed 2025-02-21 | $5.19B derived: sum of 4 quarters · filed 2025-02-21 | |
| 2022-12-31 | $1.92B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $3.02B derived: sum of 2 quarters · filed 2025-02-21 | $4.40B derived: sum of 3 quarters · filed 2025-02-21 | $5.42B 10-K · filed 2025-02-21 | |
| 2022-09-30 | $1.10B 10-Q · filed 2023-11-03 | $2.48B derived: sum of 2 quarters · filed 2023-11-03 | $3.50B 10-Q · filed 2023-11-03 | $4.45B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-06-30 | $1.38B 10-Q · filed 2023-08-03 | $2.40B 10-Q · filed 2023-08-03 | $3.35B derived: sum of 3 quarters · filed 2024-02-23 | $4.07B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-03-31 | $1.02B 10-Q · filed 2023-05-04 | $1.97B derived: sum of 2 quarters · filed 2024-02-23 | $2.69B derived: sum of 3 quarters · filed 2024-02-23 | $3.44B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2021-12-31 | $952.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $1.67B derived: sum of 2 quarters · filed 2024-02-23 | $2.42B derived: sum of 3 quarters · filed 2024-02-23 | $2.62B 10-K · filed 2024-02-23 | |
| 2021-09-30 | $722.00M 10-Q · filed 2022-11-03 | $1.47B derived: sum of 2 quarters · filed 2022-11-03 | $1.67B 10-Q · filed 2022-11-03 | $1.67B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-06-30 | $750.00M 10-Q · filed 2022-08-03 | $943.00M 10-Q · filed 2022-08-03 | $951.00M derived: sum of 3 quarters · filed 2023-02-24 | $951.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-03-31 | $193.00M 10-Q · filed 2022-05-04 | $201.00M derived: sum of 2 quarters · filed 2023-02-24 | $201.00M derived: sum of 3 quarters · filed 2023-02-24 | $201.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2020-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $8.00M derived: sum of 2 quarters · filed 2023-02-24 | $8.00M derived: sum of 3 quarters · filed 2023-02-24 | $8.00M 10-K · filed 2023-02-24 | $7.93M 10-K · filed 2021-02-26 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |